|Author (Corporate)||Cardiff EDC|
Reports and information relating to the use of the antiviral medication Remdesivir for treatment of patients diagnosed with COVID-19 (coronavirus).
This medication is sold under the brand name Veklury. It is developed by bio-pharmaceutical company Gilead Sciences.
As the COVID-19 (coronavirus) pandemic unfolded, this medication was increasingly seen as a valid treatment for patients. Research was conducted to understand the effects on tackling this virus, following effective treatment against previous respiratory syndromes.
On 30 April 2020, the European Medicines Agency (EMA) started a rolling review of data on the use of Remdesivir in COVID‑19. The application for the marketing authorisation was submitted to the EMA on 5 June. EMA’s human medicines committee (CHMP) recommended on 25 June granting a conditional marketing authorisation to Veklury for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen.
On 3 July, this medication became the first treatment to be given a conditional marketing authorisation. The authorisation was provided just days after the company allocated nearly all of its supply of Remdesivir to the United States over a period of 3 months, raising concerns about availability elsewhere. This medication had already been made available on the United Kingdom's NHS in late May.
The European Commission signed an agreement with Gilead Sciences on 28 July to secure treatment doses of Veklury. The deal aimed to ensure the treatment of approximately 30,000 patients and help to cover the existing needs over the following few months. The Commission's Emergency Support Instrument was used to finance the contract.
|Subject Tags||Medicines | Medical Devices|